| dc.creator | Cassoli, Juliana S | |
| dc.creator | Guest, Paul C | |
| dc.creator | Santana, Aline G | |
| dc.creator | Martins-de-Souza, Daniel | |
| dc.date | 2015-Dec | |
| dc.date | 2016-05-23T19:42:57Z | |
| dc.date | 2016-05-23T19:42:57Z | |
| dc.date.accessioned | 2018-03-29T01:30:09Z | |
| dc.date.available | 2018-03-29T01:30:09Z | |
| dc.identifier | Proteomics. Clinical Applications. v. 10, n. 4, 2015-Dec. | |
| dc.identifier | 1862-8354 | |
| dc.identifier | 10.1002/prca.201500109 | |
| dc.identifier | http://www.ncbi.nlm.nih.gov/pubmed/26679983 | |
| dc.identifier | http://repositorio.unicamp.br/jspui/handle/REPOSIP/235854 | |
| dc.identifier | 26679983 | |
| dc.identifier.uri | http://repositorioslatinoamericanos.uchile.cl/handle/2250/1304097 | |
| dc.description | Schizophrenia is an incurable neuropsychiatric disorder managed mostly by treatment of the patients with antipsychotics. However, the efficacy of these drugs has remained only low to moderate despite intensive research efforts since the early 1950s when chlorpromazine, the first antipsychotic, was synthesized. In addition, antipsychotic treatment can produce undesired and often severe side effects in the patients and addressing these remains a large unmet clinical need. One of the reasons for the low effectiveness of these drugs is the limited knowledge about the molecular mechanisms of schizophrenia, which impairs the development of new and more effective treatments. Recently, proteomic studies of clinical and pre-clinical samples have identified changes in the levels of specific proteins in response to antipsychotic treatment, which have converged on molecular pathways such as cell communication and signalling, inflammation and cellular growth and maintenance. The findings of these studies are summarized and discussed in this review and we suggest that this provides validation of proteomics as a useful tool for mining drug mechanisms of action and potentially for pinpointing novel molecular targets that may enable development of more effective medications. This article is protected by copyright. All rights reserved. | |
| dc.description | 10 | |
| dc.description | | |
| dc.language | eng | |
| dc.relation | Proteomics. Clinical Applications | |
| dc.relation | Proteomics Clin Appl | |
| dc.rights | fechado | |
| dc.source | PubMed | |
| dc.subject | Antipsychotics | |
| dc.subject | Proteomics | |
| dc.subject | Psychiatric Disorders | |
| dc.subject | Schizophrenia | |
| dc.title | Reviewemploying Proteomics To Unravel The Molecular Effects Of Antipsychotics And Their Role In Schizophrenia. | |
| dc.type | Artículos de revistas | |
